Company
CNSX:BUZZ
PharmaDrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs. The company owns 51% of Sairiyo Therapeutics, a biotech company specialising in researching and reformulating established natural medicines to bring them through clinical trials and the associated regulatory approval process in the US and Europe.
66 stories · page 2 of 4
The company said each debenture bears interest at a rate of 15% per annum payable monthly in arrears and it matures one year from the date of issue and is convertible into common shares at a price of $0.05
"This study outcome serves to further support our goal of moving towards an FDA clinical trial and will provide the company with the opportunity to fully leverage the benefits of the previously granted FDA orphan drug designation for cephar
Pharmadrug Production has a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union
The company said it intends to use the net proceeds from the offering to assist in the production of pharmaceutical-grade cepharanthine to be used in Phase I and Phase II clinical trials and for general working capital
The company said that the lead candidate was chosen because it displayed superior potency and a favourable toxicity profile
The Canadian company said the provisional patent was filed on April 14, 2022, to support the use of PD-001 plus cabazitaxel for primary, metastatic, and chemotherapy-resistant prostate cancer
The company said a head-to-head drug elution study of its three undisclosed DMT-analogue candidates has now been completed while supportive cell-based biocompatibility has been examined
PharmaDrug believes the FDA feedback it has received provides a path to agreements on IND-enabling studies, the design of a Phase 1/2 clinical study, and the overall clinical development plan to move PD-001 forward as an oral treatment for
The company reported that a once-per-day oral regimen of PD-001, in combination with cabazitaxel provided statistically significant benefit at the scheduled end of dosing in its ongoing prostate efficacy study
Following this successful outcome, the company, in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has initiated fabrication activities necessary to produce a novel medical device capable of delivering sustained,
“While esophageal cancer continues to be our main focus with a goal to move towards an FDA clinical trial, we believe that cepharanthine will ultimately show a wider potential use in the treatment of cancers, specifically in combination wit
Parallel development of PD-001 for oncology and infectious disease indications will provide valuable time and cost efficiencies to the company by way of eliminating the need to duplicate multiple standard activities
Hutnik will assist the company in its ongoing efforts to develop N,N-dimethyltryptamine (DMT) as a potential treatment for glaucoma
The company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification and 100% of Super Smart, a Dutch company building a modern adult-use psychedel
The US Food & Drug Administration (FDA) has provided written responses which Pharmadrug believes provide "a path to agreements on IND-enabling studies, the design of a Phase 1/2 clinical study, and the overall clinical development plan to m
The company said that it is now focusing on advancing IND-enabling studies to support future FDA clinical studies in 2022 for cepharanthine (PD-001)
The Toronto-based company said that it will be focusing on comparing the potency of two candidate tryptamines, which were narrowed from an initial list of six
While there are remaining differences in opinion about classification and sales channels, PharmaDrug believes cannabis will likely become legal within the near term as a controlled substance with expanded access.
The company believes the strategy to increase US investor ownership fits well with its growing focus on biotech research and development
The studies will examine the efficacy of cepharanthine on its own and when it is combined with standard-of care chemotherapy to support Phase 1 and 2 human clinical trials.
